EGF Outros c-met + HGF Módulo
MAPK Sobreactivaçã
o Síntese de nucleotídeos Transcrição génica Síntese proteica Activação do ciclo celular Proliferação, migração e invasão de células neoplásicas uroteliais Progressão no estadio e grau de indiferenciação, recidiva precoce, morte Raf cínases Tpl2, Mos MEKK 1-5 TAK 1 ASK 1 MLK 1-4 TAK 1 ASK 1 MEKK4 DK JNK 1-3 MKK 1,2 MKK 3, 4, 6 MKK 4, 7 p38 (, , , ) Jun RSK MEF 1 ATF 2 CHOP ERK 1, 2 Inflamação
Stress osmótico Factores de crescimentoCitoquinas Citoquinas pró-inflamatórias (TNF, IL-1) Radiação UV RAC 1 RAS GTP TRAF 6 TAB 1,2 Apoptose
Inibição do crescimento Sobrevivência celular,Crescimento e Diferenciação
Apoptose Inibição do crescimento
V. Bibliografia
1. Aguirre-Ghiso JA, Estrada Y, Liu D e Ossowski L. ERKMAPK activity as a determinant
of tumor growth and dormancy; Regulation by p38SAPK. Canc Res 2003; 63: 1684-1695.
2. Bell JT, Burney SW, Friedell GH. Blood invasion in human bladder cancer. J Urol 1971; 105: 675-8.
3. Bochner BH, Cote RJ, Weidner N, Groshen S, Chen SC, Skinner DG, Nichols PW. Angiogenesis in bladder cancer: relationship between microvessel density and tumor prognosis. J Natl Cancer Inst 1995; 87 (21): 1603-12.
4. Boucher MJ, Jean D, Vezina A e Rivard N. Dual role of MEK/ERK signaling in senescence and transformation of intestinal epithelial cells. Am J Physiol Gastrointest Liver Physiol 2004; 286(5): G736-746.
5. Bryan RT, Hussain SA, James ND, Jankowski JA, Wallace DMA. Molecular pathways in bladder cancer: part 1, BJU International 2005; 95: 485-490.
6. Bryan RT, Hussain SA, James ND, Jankowski JA, Wallace DMA. Molecular pathways in bladder cancer: part 2, BJU International 2005; 95: 491-496.
7. Buscarini M, Marcus L. Quek, Parkash Gill, Guangbin Xia, David I. Quinn, John P. Stein. Molecular prognostic factors in bladder cancer, BJU International 2005; 95, 739- 742.
8. Cancer Research UK, CancerStats, December 2002.
9. Chen L, He HY, Li HM, Zheng J, Heng WJ, You JF e Fang WG. ERK1/2 and p38 pathways are required for P2Y receptor-mediated prostate cancer invasion. Cancer Lett 2004; 215(2): 239-247.
10. Cooke PW, James ND, Ganesan R, Wallace DMA, Burton A, Young LS. CD40 expression in bladder cancer. J Pathol 1999; 188: 38–43.
11. Durdux C, Housset M. Facteurs pronostiques des tumeurs infiltrantes de vessie. Cancer/Radiother 1998; 2: 491-8.
12. Eble JN, Young RH. Carcinoma of the urinary bladder: a review of its diverse morphology. Semin Diagn Pathol 1997; 14: 98–108.
13. Fossa SD, Whire H, Aass N. Bladder cancer definitive radiation therapy of muscle- invasive bladder cancer. Cancer 1993; 72: 3036-43.
14. Frazier HA, Robertson JE, Dodge RK, Paulson MS, Aans DF. The value of pathologic factors in predicting cancer specific survival among patients treated with radical cystectomy for transitional cell carcinoma of the bladder and prostate. Cancer 1993; 71: 3993-4001.
15. Fung CY, Shipley WU, Young RH et al. Prognostic factors in invasive bladder carcinoma in a prospective trial of preoperative adjuvant chemotherapy and radiotherapy. J Clin Oncol 1991; 9: 1533-42.
16. Gospodarowicz MK, Hawkins NV, Rawlings GA. Radical radiotherapy for muscle invasive transitional cell carcinoma of the bladder: failure analysis. J Urol 1989; 136: 1448-54.
17. Greenlee RT, Murray T, Bolden S, Wingo PA. Statistics 2000. CA Cancer J Clin 2000; 50: 7–33.
18. Grossman HB, Lee C, Bromberg J, Liebert M. Expression of the alpha-6-beta-4 integrin provides prognostic information in bladder cancer. Oncol Rep 2000; 7: 13–6.
19. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57–70.
20. Heney NM, Proppe K, Prout GR, Griffin PP, Shipley WU. Invasive bladder cancer: tumor configuration, lymphatic invasion and survival. J Urol 1983; 130: 897-7.
21. Housset M, Maulard C, Chrétien Y, Dufour B. Combined radiation and chemotherapy for invasive transitional-cell carcinoma of the bladder: a prospective study. J Clin Oncol 1993; 11: 2150-7.
22. Huot J, Houle F, Marceau F e Landry J. Oxidative stress-induced actin reorganization mediated by the p38 mitogen-activated protein kinase/heat shock protein 27 pathway in vascular endothelial cells. Circ Res 1997; 80:383-392.
23. Huot J, Houle F, Spitz DR e Landry J. HSP27 phosphorylation-mediated resistance against actin fragmentation and cell death induced by oxidative stress. Cancer Res 1996; 56: 273-279.
24. Ikenoue T, Hikiba Y, Kanai F, Tanaka Y, Imamura J, Imamura T, Ohta M, Ijichi H, Tateishi K, Kawakami T, Aragaki J, Matsumura M, Kawabe T e Omata M. Functional analysis of mutations within the kinase activation segment of B-Raf in human colorectal tumors. Cancer Res 2003; 63(23): 8132-8137.
25. Jahnson S, Pederson J, Westman G. Bladder carcinoma:a 20 year review of radical radiation therapy. Radiother Oncol 1991; 22: 111-7.
26. James M. Olson, Andrew R. Hallahan. P38 MAP kinase: a convergence point in câncer therapy, Trends in Molecular Medicine 2004; 10 (3).
27. Jaworski M, Buchmann A, Bauer P, Riess O e Schwarz M. B-Raf and Ha-ras mutations in chemically induced mouse liver tumors. Oncogene 2004; December.
28. Kaladhar B. Reddy, Sanaa M. Nabha, Natasha Atanaskova. Role of MAP kinase in tumor progression and invasion, Câncer and Metastasis Reviews 2003; 22: 395-403. 29. Kaminska K. MAPK signalling pathways as molecular targets for anti-inflamatory
therapy – from molecular mechanisms to therapeutic benefits, Biochimica et Biophysyca Acta 2005; 1754: 253-262.
30. Kaufman DS, Shipley WU, Althausen AF. Radiotherapy and chemotherapy in invasive bladder cancer with potential bladder sparing. Hematol Oncol clin North Am 1992; 6: 179-94.
31. Kaufman DS, Shipley WU, Griffin PP. Selective bladder preservation by combined modality treatment of invasive bladder cancer. N Engl J Med 1993; 329: 1377-81. 32. Kim TI, Jin SH, Kim WH, Kang EH, Choi KY, Kim HJ, Shin SK, Kang JK. Prolonged
activation of mitogen-activated protein kinases during NSAID-induced apoptosis in HT- 29 colon cancer cells. Int J Colorectal Dis 2001; 16 (3):167-73.
33. Kramer BW, Gotz R e Rapp UR. Use of mitogenic cascade blockers for treatment of C- Raf induced lung adenoma in vivo: CI-1040 strongly reduces growth and improves lung structure. BMC Cancer 2004; 4 (1): 24.
34. Lancelin F, Anidjar M, Villette JM, Soliman A, Teillac P, Le Duc A, Fiet J, Cussenot O. Telomerase activity as a potential marker in preneoplastic bladder lesions. BJU Int 2000; 85 (4): 526-31.
35. Larsen MP, Steinberg GD, Brendler CB, Epstein JI. Use of Ulex europaeus agglutinin I (UEA) to distinguish vascular and pseudovascular invasion in transitional-cell carcinoma of bladder with lamina propria invasion. Mod Pathol 1990; 3: 83-88.
36. Mameghan H, Fisher RJ, Watt WH. The management of invasive transitional cell carcinoma of the bladder: results of definitive and preoperative radiation therapy in 390 patients treated at the Prince of Walles Hospital, Sydney, Australia. Cancer 1992; 69: 2771-8.
37. Medema RH, Bos JL. The role of p21-ras in receptor tyrosine kinase signalling. Crit Rev Oncog 1993; 4: 615–61.
38. Meloche S, Pouysségur J. The ERK1/2 mitogen-activated protein kinase pathway as a master regulator of the G1- to S-phase transition. Oncogene 2007; 26: 3227–3239.
39. ONS Report. Registrations of cancer diagnosed in 1993–96, England and Wales. Health Statistics Quarterly (Office for National Statistics) Winter, 1999.
40. Oosterlinck W, Lobel B, Jakse G, Malmstrom P, Stocklec M, Sternberg C. Guidelines on Bladder Cancer, Eur Urol 2002; 41:105-112.
41. Palou J, Bohle A, Witjes A, Colombel M, Brausi M, Lamm D, Persad R, Buckley, Akaza H, Soloway M. Diagnosis of Non-Muscle Invasive Bladder Cancer. Eur Urol Sup 2008; 7: 627-36.
42. Pashos CL, Botteman MF, Laskin MF, Redaelli A. Bladder Câncer: Epidemiology, Diagnosis, and Management. Cancer Practice 2002; 10 (6): 311-322.
43. Pouyssegur J, Volmat V, Lenormand P. Fidelity and spatio-temporal control in MAP kinase (ERKs) signalling. Biochem Pharmacol 2002; 64: 755–63.
44. Price DT, Rocca GD, Guo C, Ballo MS, Schwinn DA e Luttrell LM. Activation of extracellular signal-regulated kinase in human prostate cancer. J Urol 1999; 162 (4): 1537-1542.
45. Ramani P, Birch BRP, Harland SJ, Parkinson MC. Evaluation of endothelial markers in detecting blood and lymphatic channel invasion in pT1 transitionl carcinoma of the bladder. Hystopathology 1991; 19: 551-4.
46. Sebolt-Leopold J e Herrera R. Targeting the mitogen-activated protein kinase cascade to treat cancer. Nat Rev Canc 2004; 4: 937-947.
47. Sengelov L, Horn T, Steven K. p53 nuclear immunoreactivity as a predictor of response and outcome following chemotherapy for metastatic bladder cancer. J Cancer Res Clin Oncol 1997; 123: 565-70.
48. Shipley WU, Prout GR, Kaufman DS, Perone TL. Invasive bladder carcinoma: the importance of initial transurethral surgery and other significant prognostic factors for improved survival with full-dose irradiation. Cancer 1987; 60: 514.
49. Slack NH, Prout GR Jr. The heterogeneity of invasive bladder carcinoma and different responses to treatment. J Urol 1980; 123: 644-652.
50. Soloway MS, Lopez AE, Patel J, Lu Y. Results of radical cystectomy for transitional cell carcinoma of the bladder and the effect of chemotherapy. Cancer 1994; 73: 1926- 31.
51. Stein JP, Grossfel GD, Ginsberg DA et al. Prognostic markers in bladder cancer: a contemporary review of the literature, J Urol 1998; 160 (3.1): 645-59.
52. Strumberg D, Richly H, Hilger RA, Schleucher N, Korfee S, Tewes M, Faghih M, Brendel E, Voliotis D, Haase CG, Schwartz B, Awada A, Voigtmann R, Scheulen ME, Seeber S. Phase I Clinical and Pharmacokinetic Study of the Novel Raf Kinase and Vascular Endothelial Growth Factor Receptor Inhibitor BAY 43-9006 in Patients With Advanced Refractory Solid Tumors. Clin Oncol 2004; December.
53. Swiatkowski S, Seifert HH, Steinhoff C, Prior A, Thievessen I, Schliess F, Schulz WA. Activities of MAP-Kinase Pathways in Normal Uroepithelial Cells and Urothelial Carcinoma Cell Lines, Experimental Cell Research 2003; 282: 48-57.
54. Torben F. Orntoft, Hans Wolf. Molecular alterations in bladder cancer, Urol Res 1998; 26, 223-233.
55. Trasher JB, Frazier HA, Robertson JE, Dodge RK, Paulson DF. Clinical variables which serve as predictors of cancer-specific survival among patients treated with radical cystectomy for transitional cell carcinoma of the bladder and prostate. Cancer 1994; 73: 1708-15.
56. Vihinen P, Kähäri VM. Matrix metalloproteinases in cancer: prognostic markers and therapeutic targets. Int J Cancer 2002 May; 99 (2): 157-66.
57. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, Cao Y, Shujath J, Gawlak S, Eveleigh D, Rowley B, Liu L,
Adnane L, Lynch M, Auclair D, Taylor I, Gedrich R, Voznesensky A, Riedl B, Post LE, Bollag G e Trail PA. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004 ; 64(19): 7099-7109.